Structure Therapeutics Past Earnings Performance
Past criteria checks 0/6
Structure Therapeutics's earnings have been declining at an average annual rate of -37.5%, while the Pharmaceuticals industry saw earnings declining at 0.8% annually.
Key information
-37.5%
Earnings growth rate
32.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -19.8% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How Structure Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -90 | 33 | 70 |
| 30 Sep 23 | 0 | -77 | 26 | 58 |
| 30 Jun 23 | 0 | -66 | 21 | 50 |
| 31 Mar 23 | 0 | -58 | 18 | 41 |
| 31 Dec 22 | 0 | -53 | 16 | 36 |
| 30 Sep 22 | 0 | -56 | 15 | 38 |
| 31 Dec 21 | 0 | -44 | 9 | 29 |
Quality Earnings: GPCR is currently unprofitable.
Growing Profit Margin: GPCR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if GPCR's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare GPCR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GPCR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.7%).
Return on Equity
High ROE: GPCR has a negative Return on Equity (-19.79%), as it is currently unprofitable.